U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 3 of 3 results

Status:
US Approved Rx (2023)
First approved in 2022

Class (Stereo):
CHEMICAL (ABSOLUTE)



Bexagliflozin, also known as EGT1442, is a potent and selective SGLT2 inhibitor. Bexagliflozin is under investigation for the treatment of Type 2 Diabetes Mellitus. Bexagliflozin has been investigated for the treatment of Diabetes Mellitus and Type2 ...
Status:
Possibly Marketed Outside US

Class:
PROTEIN

Status:
US Approved Rx (2023)
First approved in 2022

Class (Stereo):
CHEMICAL (ABSOLUTE)



Bexagliflozin, also known as EGT1442, is a potent and selective SGLT2 inhibitor. Bexagliflozin is under investigation for the treatment of Type 2 Diabetes Mellitus. Bexagliflozin has been investigated for the treatment of Diabetes Mellitus and Type2 ...